Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized Trial

Samuel T. Wilkinson, MD; Brandon M. Kitay, MD, PhD; Matthew Macaluso, DO; Mia C. Santucci, BA; Kristina Kumpf, MA; Cindy Voghell, BS; Lauren Astorino, MSN; Rachel Hershenberg, PhD; Valeria Martinez-Kaigi, PhD; Tiffany Nowell, PhD; Michael E. Thase, MD; Gerard Sanacora, MD, PhD; T. Greg Rhee, PhD

J Clin Psychiatry 2026;87(2):25m16285

Abstract

Background: Suicide is a public health crisis in the US, with limited evidence demonstrating efficacy of treatments for high-risk patients due in part to their exclusion from most clinical trials. This clinical trial evaluates the feasibility and efficacy of adjunctive cognitive behavioral therapy (CBT) with esketamine in patients with major depression and suicidal ideation (MDSI).

Methods: Treatment-seeking patients (57 inpatients; 36 outpatients) with major depressive disorder (DSM-5 criteria) and suicidal ideation were randomized (1:1) to receive esketamine plus a 16-week course of CBT or esketamine plus treatment as usual (TAU) alone. The starting dose of esketamine was 84 mg in both groups. The primary outcome was feasibility, with a key secondary outcome being improvement in suicidal ideation. CBT consisted of traditional one-on-one therapy sessions and a computer-assisted program to facilitate psychoeducation and attainment of skills. Enrollment occurred between March 2021 and May 2025.

Outcomes: Ninety-three subjects were randomized with a 72% study completion rate, demonstrating feasibility (primary outcome) by meeting recruitment goals of 80% of the targeted enrollment and 70% of retention through study end point. Change in suicidal ideation from baseline through week 18 (a key secondary outcome), based on the Beck Scale for Suicidal Ideation (BSSI), Clinician Global Improvement Scale for Suicide Severity (CGI-S), and Montgomery-Åsberg Depression Rating Scale (MADRS), favored the CBT group over the TAU group (BSSI mean difference of –1.91, 95% CI –3.57 to –0.24, P=.025; CGI-S mean difference of –0.33, 95% CI –0.58 to –0.08, P=.011; MADRS mean difference of –3.77, 95% CI –6.62 to –0.93, P=.009). No difference between groups was observed in the Columbia-Suicide Severity Rating Scale score, MADRS-SI score, or suicide-related events.

Interpretation: This study demonstrates the feasibility and the effectiveness of combining CBT with esketamine to reduce SI and prevent relapse in patients with MDSI.

Trial Registration: ClinicalTrials.gov identifier: NCT04760652.

J Clin Psychiatry 2026;87(2):25m16285

Author affiliations are listed at the end of this article.

Members Only Content

This full article is available exclusively to Professional tier members. Subscribe now to unlock the HTML version and gain unlimited access to our entire library plus all PDFs. If you're already a subscriber, please log in below to continue reading.

Subscribe Now

Already a member? Log in

References (33)

Zwald ML, Holland KM, Annor FB, et al. Syndromic Surveillance of Suicidal Ideation and Self-Directed Violence - United States, January 2017-December 2018. MMWR Morb Mortal Wkly Rep. 2020;69(4):103–108. PubMed CrossRef
Curtin SC, Warner M, Hedegaard H. Increase in Suicide in the United States, 1999-2014. NCHS Data Brief. 2016;241:1–8. PubMed
Bommersbach TJ, McKean AJ, Olfson M, et al. National trends in mental health-related emergency department visits among youth, 2011-2020. JAMA. 2023;329(17):1469–1477. PubMed CrossRef
Bommersbach TJ, Olfson M, Rhee TG. National trends in emergency department visits for suicide attempts and intentional self-harm. Am J Psychiatry. 2024;181(8):741–752. PubMed CrossRef
Cavanagh JT, Carson AJ, Sharpe M, et al. Psychological autopsy studies of suicide: a systematic review. Psychol Med. 2003;33(3):395–405. PubMed CrossRef
Conwell Y, Duberstein PR, Cox C, et al. Relationships of age and axis I diagnoses in victims of completed suicide: a psychological autopsy study. Am J Psychiatry. 1996;153(8):1001–1008. PubMed CrossRef
Iltis AS, McCall WV, Deria R. Suicidality, depression, and the FDA: health inequities and the ethical conduct of research. J Clin Psychiatry. 2020;81(2):19m13050. PubMed CrossRef
Iltis AS, Misra S, Dunn LB, et al. Addressing risks to advance mental health research. JAMA Psychiatry. 2013;70(12):1363–1371. PubMed CrossRef
Wilkinson ST, Bryan CJ, Alphs LD, et al. Making progress in clinical trials for suicide prevention: a review. JAMA Psychiatry. 2025;82(4):420–426. PubMed CrossRef
Grunebaum MF, Galfalvy HC, Choo TH, et al. Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial. Am J Psychiatry. 2018;175(4):327–335. PubMed CrossRef
Fu DJ, Ionescu DF, Li X, et al. Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I). J Clin Psychiatry. 2020;81(3):19m13191. PubMed CrossRef
Ionescu DF, Fu DJ, Qiu X, et al. Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a phase 3, double-blind, randomized study (ASPIRE II). Int J Neuropsychopharmacol. 2021;24(1):22–31. PubMed CrossRef
Katz IR, Rogers MP, Lew R, et al. Lithium treatment in the prevention of repeat suicide-related outcomes in veterans with major depression or bipolar disorder: a randomized clinical trial. JAMA Psychiatry. 2022;79(1):24–32. PubMed CrossRef
Bryan CJ, Simon P, Wilkinson ST, et al. A digital therapeutic intervention for inpatients with elevated suicide risk: a randomized clinical trial. JAMA Netw Open. 2025;8(8):e2525809. PubMed CrossRef
Canuso CM, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2018;175(7):620–630. PubMed CrossRef
Daly EJ, Trivedi MH, Janik A, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2019;76(9):893–903. PubMed CrossRef
Chung DT, Ryan CJ, Hadzi-Pavlovic D, et al. Suicide rates after discharge from psychiatric facilities: a systematic review and meta-analysis. JAMA Psychiatry. 2017;74(7):694–702. PubMed CrossRef
Hollon SD, DeRubeis RJ, Shelton RC, et al. Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Arch Gen Psychiatry. 2005;62(4):417–422. PubMed CrossRef
Sim K, Lau WK, Sim J, et al. Prevention of relapse and recurrence in adults with major depressive disorder: systematic review and meta-analyses of controlled trials. Int J Neuropsychopharmacol. 2015;19(2):pyv076. PubMed CrossRef
Brown GK, Ten Have T, Henriques GR, et al Cognitive therapy for the prevention of suicide attempts: a randomized controlled trial. JAMA. 2005;294(5):563–570. PubMed CrossRef
Rudd MD, Bryan CJ, Wertenberger EG, et al. Brief cognitive-behavioral therapy effects on post-treatment suicide attempts in a military sample: results of a randomized clinical trial with 2-year follow-up. Am J Psychiatry. 2015;172(5):441–449. PubMed CrossRef
Wilkinson ST, Wright D, Fasula MK, et al. Cognitive behavior therapy may sustain antidepressant effects of intravenous ketamine in treatment-resistant depression. Psychother Psychosom. 2017;86(3):162–167. PubMed CrossRef
Wilkinson ST, Rhee TG, Joormann J, et al. Cognitive behavioral therapy to sustain the antidepressant effects of ketamine in treatment-resistant depression: a randomized clinical trial. Psychother Psychosom. 2021;90(5):318–327. PubMed CrossRef
Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42(2):377–381. PubMed CrossRef
Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inf. 2019;95:103208. PubMed CrossRef
Hopewell S, Chan AW, Collins GS, et al. CONSORT 2025 statement: updated guideline for reporting randomised trials. BMJ. 2025;389:e081123. PubMed CrossRef
Kitay BM, Murphy E, Macaluso M, et al. Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: the CBT-ENDURE randomized clinical trial study protocol. Psychiatry Res. 2023;330:115585. PubMed CrossRef
Jarrett RB, Vittengl JR, Clark LA, et al. Skills of Cognitive Therapy (SoCT): a new measure of patients’ comprehension and use. Psychol Assess. 2011;23(3):578–586. PubMed CrossRef
Wright JH, Wright AS, Salmon P, et al. Development and initial testing of a multimedia program for computer-assisted cognitive therapy. Am J Psychother. 2002;56(1):76–86. PubMed CrossRef
U.S. Food and Drug Administration. Guidance for industry: suicidal ideation and behavior: prospective assessment of occurrence in clinical trials. 2012. Accessed January 12, 2026. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-suicidal-ideation-and-behavior-prospective-assessment-occurrence-clinical-trials
Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266–1277. PubMed CrossRef
Price RB, Spotts C, Panny B, et al. A novel, brief, fully automated intervention to extend the antidepressant effect of a single ketamine infusion: a randomized clinical trial. Am J Psychiatry. 2022;179(12):959–968. PubMed CrossRef
Olfson M. Suicide risk after psychiatric hospital discharge. JAMA Psychiatry. 2017;74(7):669–670. PubMed CrossRef